SOUTHAMPTON, England--(BUSINESS WIRE)--Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback